Sleep Medicine
Sleep Medicine, Narcolepsy & the Science of Wakefulness
Exploring Orexin Biology, Neurological Sleep Disorders & Advances in Sleep-Wake Medicine
Sleep is a fundamental neurological process essential to cognition, cardiovascular health, metabolic regulation, emotional well-being, and physical recovery.
At Park Avenue Medicine & Surgery, we recognize that understanding sleep requires more than evaluating how many hours a person spends in bed. Normal sleep and wakefulness depend on complex interactions among neurological signaling pathways, circadian rhythms, respiratory function, and multiple physiological systems.
Recent developments in sleep medicine have brought renewed attention to the neurobiology of wakefulness, particularly the role of orexin (hypocretin) in maintaining alertness and regulating transitions between sleep and waking.
The emergence of orexin-targeted therapies represents an important scientific development, illustrating how a deeper understanding of disease mechanisms can lead to new therapeutic strategies.
Our educational focus includes narcolepsy, central disorders of hypersomnolence, sleep-wake neurobiology, established treatment modalities, and advances in mechanism-directed medicine.
Understanding Narcolepsy: A Neurological Disorder of Sleep-Wake Regulation
Narcolepsy is a chronic neurological disorder characterized by the brain's impaired ability to regulate normal sleep-wake transitions.
Although excessive daytime sleepiness is a hallmark symptom, narcolepsy is considerably more complex than simply feeling tired.
Patients may experience:
Excessive daytime sleepiness and involuntary sleep episodes
Cataplexy, or sudden episodes of muscle weakness triggered by emotion
Sleep paralysis
Hypnagogic or hypnopompic hallucinations
Fragmented nighttime sleep
Difficulty maintaining attention and concentration
Impaired social, occupational, and academic functioning
Narcolepsy is divided into two principal categories.
Narcolepsy Type 1 (NT1) is strongly associated with deficiency of the neuropeptide orexin and typically involves cataplexy or documented low cerebrospinal fluid hypocretin-1 levels.
Narcolepsy Type 2 (NT2) is characterized by excessive daytime sleepiness without cataplexy and generally without the profound orexin deficiency characteristic of NT1.
Distinguishing these conditions from insufficient sleep, obstructive sleep apnea, idiopathic hypersomnia, circadian rhythm disorders, and medication-related somnolence is fundamental to accurate diagnosis.
Orexin (Hypocretin): The Neurobiology of Wakefulness
One of the most important discoveries in modern sleep neuroscience has been the identification of orexin, also known as hypocretin.
Orexin is produced by a relatively small population of neurons in the lateral hypothalamus and adjacent regions.
Despite their limited number, these neurons influence extensive neural networks responsible for sustaining wakefulness and regulating sleep architecture.
Orexin signaling helps coordinate several essential functions:
Maintenance of consolidated wakefulness
Regulation of REM sleep transitions
Stabilization of muscle tone during wakefulness
Attention and vigilance
Interactions between circadian regulation and arousal
Responses involving energy balance, motivation, and physiological activity
Two orexin receptors, OX1R and OX2R, mediate important aspects of these signaling pathways.
In narcolepsy type 1, the loss of orexin-producing neurons results in markedly diminished orexin signaling.
This disrupts the brain's capacity to maintain stable wakefulness and suppress inappropriate REM-sleep phenomena during waking hours.
The loss of orexin-producing neurons is thought to involve immune-mediated mechanisms in susceptible individuals, although the precise causal pathways remain incompletely understood.
Understanding this biological deficit has significantly influenced the direction of contemporary narcolepsy research.
From Symptom Management to Mechanism-Directed Treatment
Historically, narcolepsy treatment focused largely on controlling individual symptoms.
Wake-promoting agents and stimulants have been used to address excessive daytime sleepiness, while other medications have been used to reduce cataplexy and improve nighttime sleep.
These therapies remain important components of individualized clinical care.
However, identifying orexin deficiency as a central mechanism in narcolepsy type 1 created an opportunity to develop treatments directed toward the underlying neurochemical abnormality.
Orexin receptor agonists activate orexin signaling pathways, potentially compensating for the loss of endogenous orexin activity.
This approach differs mechanistically from conventional stimulants and other established narcolepsy therapies.
It also illustrates a broader evolution in medicine: transitioning from predominantly symptom-directed treatment toward therapies informed by identifiable disease mechanisms.
The clinical implications of this development extend beyond pharmacology. They invite renewed examination of diagnostic precision, treatment outcomes, long-term safety, patient-reported functioning, and how neurological disorders are classified and managed.
Oveporexton: A Milestone in Orexin Receptor Pharmacology
In August 2026, the U.S. Food and Drug Administration approved oveporexton (ORZEYFUL), developed by Takeda, for the treatment of narcolepsy type 1 in adults.
Oveporexton is the first FDA-approved oral orexin receptor 2 (OX2R) agonist.
Rather than acting as a traditional central nervous system stimulant, oveporexton selectively activates OX2R pathways involved in maintaining wakefulness.
Two pivotal Phase 3 clinical trials, FirstLight and RadiantLight, evaluated the medication in patients with narcolepsy type 1.
The studies demonstrated statistically significant improvements compared with placebo in measures including:
Objective wakefulness assessed by the Maintenance of Wakefulness Test
Subjective daytime sleepiness measured by the Epworth Sleepiness Scale
Frequency of cataplexy episodes
The trials also evaluated a broader spectrum of symptoms associated with narcolepsy type 1.
Reported adverse effects included insomnia, urinary frequency, urinary urgency, and increased salivation.
Although these findings represent an important advance in the treatment of NT1, questions concerning long-term outcomes, treatment selection, real-world effectiveness, tolerability, and comparative effectiveness remain relevant to ongoing clinical evaluation.
Oveporexton does not regenerate lost orexin neurons or cure narcolepsy. Its therapeutic strategy is to activate receptor pathways ordinarily stimulated by endogenous orexin.
The significance of this development is not simply the introduction of another medication, but the clinical validation of orexin receptor agonism as a therapeutic mechanism.
The Broader Landscape of Narcolepsy Therapeutics
Modern narcolepsy management encompasses multiple pharmacological mechanisms.
Important therapeutic categories include:
Wake-Promoting Agents
Modafinil, armodafinil, and solriamfetol are used in appropriate clinical settings to address excessive daytime sleepiness through mechanisms distinct from orexin receptor agonism.
Histaminergic Therapies
Pitolisant acts through histamine H3 receptor pathways and offers a nontraditional approach to improving wakefulness and managing certain narcolepsy symptoms.
Oxybate-Based Therapies
Sodium oxybate and low-sodium oxybate formulations have established roles in selected patients with narcolepsy, including the management of cataplexy and excessive daytime sleepiness.
Traditional Stimulants
Methylphenidate and selected amphetamine-based medications remain considerations in individualized treatment planning.
Behavioral and Supportive Interventions
Consistent sleep schedules, planned naps, accommodations for daily activities, and education regarding safety and functioning remain important elements of comprehensive management.
The evolution of narcolepsy therapy highlights the importance of understanding different mechanisms of action rather than regarding all wake-promoting medications as clinically interchangeable.
Orexin Agonists Versus Orexin Antagonists: Two Different Therapeutic Strategies
The orexin system is particularly interesting because increasing and decreasing orexin signaling can serve opposite clinical objectives.
Orexin receptor agonists stimulate receptor activity and are being used or investigated for disorders involving impaired wakefulness.
Conversely, dual orexin receptor antagonists (DORAs), including suvorexant, lemborexant, and daridorexant, reduce wake-promoting signaling and are approved for the treatment of insomnia.
These opposing strategies demonstrate the importance of normal neurochemical balance.
The same signaling system can be therapeutically targeted in different directions depending on the underlying disorder.
This distinction also reinforces the need for diagnostic specificity and careful interpretation of pharmacological mechanisms.
Beyond Narcolepsy: The Spectrum of Sleep Medicine
Sleep medicine encompasses multiple disorders involving distinct neurological, respiratory, and behavioral mechanisms.
Obstructive Sleep Apnea
Obstructive sleep apnea involves recurrent episodes of upper-airway obstruction during sleep, producing fragmented sleep, intermittent hypoxemia, and potentially excessive daytime sleepiness.
Treatment options include positive airway pressure therapy, oral appliances, weight management, positional interventions, and selected procedural therapies.
Chronic Insomnia
Insomnia involves difficulty initiating or maintaining sleep, or impaired sleep quality, accompanied by daytime consequences.
Cognitive Behavioral Therapy for Insomnia (CBT-I) is a first-line therapeutic approach. Pharmacological treatments may also be considered when clinically appropriate.
Idiopathic Hypersomnia
Idiopathic hypersomnia is characterized by persistent excessive sleepiness that cannot be adequately explained by insufficient sleep or other common conditions.
Its pathophysiology remains incompletely understood, making continued clinical research particularly important.
Circadian Rhythm Sleep-Wake Disorders
Disorders of circadian timing can substantially disrupt sleep quality, daytime alertness, and physiological performance.
Treatment approaches may include timed light exposure, behavioral scheduling, and appropriately selected chronobiological interventions.
Restless Legs Syndrome and Sleep-Related Movement Disorders
These conditions can interfere with sleep initiation, sleep continuity, and restorative rest.
Evaluation may involve medication review, iron status assessment, and disorder-specific treatment.
Sleep Medicine, Chronic Pain & Rehabilitation
Sleep disorders are particularly relevant to Physical Medicine & Rehabilitation and Pain Medicine because sleep and physical function are closely interconnected.
Chronic pain may disrupt sleep initiation, continuity, and overall sleep quality. Conversely, inadequate or fragmented sleep can alter pain processing, impair rehabilitation participation, and affect daily functioning.
Sedating medications, opioids, neurological disease, impaired mobility, and sleep-disordered breathing can further complicate this relationship.
Understanding these interactions is important when evaluating patients who present with fatigue, cognitive difficulties, reduced functional capacity, and chronic musculoskeletal complaints.
A multidisciplinary approach can help distinguish primary sleep disorders from sleep disturbances secondary to other medical conditions.
Advancing Physician Education & Scientific Exchange
The rapid evolution of sleep neuroscience creates opportunities for meaningful clinical education and interdisciplinary scientific exchange.
Important subjects for professional discussion include:
The biology of orexin deficiency in narcolepsy type 1
The differences between NT1, NT2, and idiopathic hypersomnia
Recognition of excessive daytime sleepiness in clinical practice
Interpretation of Maintenance of Wakefulness Test and Epworth Sleepiness Scale outcomes
Emerging receptor-selective pharmacology
Clinical trial design, efficacy endpoints, and safety interpretation
Translating neurological research into evidence-based clinical decision-making
Functional outcomes, cognition, quality of life, and patient-centered care
As the therapeutic landscape evolves, clinicians across multiple specialties benefit from clear, scientifically grounded discussion of both established treatments and emerging approaches.
A Physician's Perspective: Karan Johar, MD
Karan Johar, MD is board-certified in Physical Medicine & Rehabilitation and Pain Medicine and serves as an Adjunct Assistant Professor in the Department of Rehabilitation Medicine at NYU Grossman School of Medicine.
He is also President of the New York Physician Society, an organization focused on professional connections, interdisciplinary dialogue, and engagement among healthcare professionals.
His clinical background emphasizes the relationship between neurological function, chronic pain, physical performance, recovery, and patient quality of life.
From a rehabilitation perspective, sleep-wake disorders are especially significant because their consequences extend beyond sleep itself, affecting cognition, participation in daily activities, occupational performance, and independence.
Dr. Johar has a professional interest in advances that connect basic neuroscience, emerging pharmacology, and measurable improvements in human function.
The development of orexin-targeted therapies provides a compelling example of how translational neuroscience may change the understanding and management of complex neurological conditions.
Looking Ahead: The Future of Sleep-Wake Medicine
Sleep medicine is entering a period of significant scientific development.
Advances in receptor pharmacology, neurobiology, diagnostic testing, and clinical outcome measurement are creating opportunities to approach sleep-wake disorders with greater precision.
Future areas of investigation include the long-term clinical effects of orexin receptor agonism, improved identification of narcolepsy and hypersomnolence disorders, treatment individualization, and exploration of additional conditions involving orexin-related pathways.
As these developments progress, rigorous clinical research and multidisciplinary physician education will remain essential.
At Park Avenue Medicine & Surgery, we value evidence-based medical advancement, interdisciplinary collaboration, and the exchange of scientific knowledge that contributes to better patient care.
Selected Scientific References
U.S. Food and Drug Administration. FDA Approves First Drug to Treat the Full Range of Narcolepsy Type 1 Symptoms. August 5, 2026.
Oveporexton for Narcolepsy Type 1 — Results from Two Phase 3 Trials. New England Journal of Medicine. September 2026;395:1166–1179. DOI: 10.1056/NEJMoa2601598.
Oveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 1. New England Journal of Medicine. DOI: 10.1056/NEJMoa2405847.
American Academy of Sleep Medicine. Treatment of Central Disorders of Hypersomnolence: An American Academy of Sleep Medicine Clinical Practice Guideline. Journal of Clinical Sleep Medicine. 2021. (Published before the approval of oveporexton.)
Medical Education & Professional Collaboration
Park Avenue Medicine & Surgery welcomes appropriate professional dialogue concerning sleep-wake neuroscience, neuropharmacology, rehabilitation, and emerging medical advances.
For inquiries regarding physician education, scientific discussion, interdisciplinary programming, or professional collaboration, please contact our administration.
This page is intended for general scientific and educational purposes. Discussion of a medication or clinical study does not constitute a product endorsement, a claim of manufacturer affiliation, or individualized medical advice. Dr. Johar's board certifications are in Physical Medicine & Rehabilitation and Pain Medicine, not Sleep Medicine. Diagnosis and management of specialized sleep disorders should involve appropriately qualified clinicians.